Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
Cédric Louvet, Gregory L. Szot, Jiena Lang, et al.
Proceedings of the National Academy of Sciences (2008) Vol. 105, Iss. 48, pp. 18895-18900
Open Access | Times Cited: 214

Showing 26-50 of 214 citing articles:

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
Paolo Fraticelli, Barbara Gabrielli, Giovanni Pomponio, et al.
Arthritis Research & Therapy (2014) Vol. 16, Iss. 4, pp. R144-R144
Open Access | Times Cited: 105
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen E. Gitelman, Brian N. Bundy, Ele Ferrannini, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 502-514
Open Access | Times Cited: 91
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer
Anja Karlstaedt, Javid J. Moslehi, Rudolf A. de Boer
Nature Reviews Cardiology (2022) Vol. 19, Iss. 6, pp. 414-425
Open Access | Times Cited: 56
New insights into the role of mast cells in autoimmunity: Evidence for a common mechanism of action?
Margaret E. Walker, Julianne K. Hatfield, Melissa A. Brown
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2011) Vol. 1822, Iss. 1, pp. 57-65
Open Access | Times Cited: 107
Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy?
Melissa A. Brown, Julianne K. Hatfield
Frontiers in Immunology (2012) Vol. 3
Open Access | Times Cited: 106
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility
Nicolas Couturier, Florence Bucciarelli, Ramil Nurtdinov, et al.
Brain (2011) Vol. 134, Iss. 3, pp. 693-703
Open Access | Times Cited: 105
Immune mediators of chronic pelvic pain syndrome
Stephen F. Murphy, Anthony J. Schaeffer, Praveen Thumbikat
Nature Reviews Urology (2014) Vol. 11, Iss. 5, pp. 259-269
Open Access | Times Cited: 94
Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Athanasios Fountas, Leonidas Nikolaos Diamantopoulos, Agathocles Tsatsoulis
Trends in Endocrinology and Metabolism (2015) Vol. 26, Iss. 11, pp. 643-656
Closed Access | Times Cited: 88
Kinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis
Gautam Patel, Caitlin E. Karver, Ranjan Kumar Behera, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 10, pp. 3820-3832
Open Access | Times Cited: 72
Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia
Jill Samis, Paul Lee, Donald Zimmerman, et al.
Pediatric Blood & Cancer (2016) Vol. 63, Iss. 8, pp. 1332-1338
Closed Access | Times Cited: 65
Inhibition of VEGF (Vascular Endothelial Growth Factor)-A or its Receptor Activity Suppresses Experimental Aneurysm Progression in the Aortic Elastase Infusion Model
Baohui Xu, Yasunori Iida, Keith Glover, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2019) Vol. 39, Iss. 8, pp. 1652-1666
Open Access | Times Cited: 63
The role of beta-cell dysfunction in early type 1 diabetes
Emily K. Sims, Raghavendra G. Mirmira, Carmella Evans‐Molina
Current Opinion in Endocrinology Diabetes and Obesity (2020) Vol. 27, Iss. 4, pp. 215-224
Open Access | Times Cited: 56
An accomplice more than a mere victim: The impact of β-cell ER stress on type 1 diabetes pathogenesis
Gulcan Semra Sahin, Hugo Lee, Feyza Engin
Molecular Metabolism (2021) Vol. 54, pp. 101365-101365
Open Access | Times Cited: 51
Tyrosine Kinase Inhibitors Ameliorate Autoimmune Encephalomyelitis in a Mouse Model of Multiple Sclerosis
Oliver Crespo, Stacey Kang, Richard Daneman, et al.
Journal of Clinical Immunology (2011) Vol. 31, Iss. 6, pp. 1010-1020
Open Access | Times Cited: 70
Therapeutic Targeting of Syk in Autoimmune Diabetes
Lucrezia Colonna, Geoffrey Catalano, Claude Chew, et al.
The Journal of Immunology (2010) Vol. 185, Iss. 3, pp. 1532-1543
Open Access | Times Cited: 68
Tec Family Kinases in Inflammation and Disease
Nicole J. Horwood, Ania M. Urbaniak, Lynett Danks
International Reviews of Immunology (2012) Vol. 31, Iss. 2, pp. 87-103
Closed Access | Times Cited: 68
Current and Future Immunomodulation Strategies to Restore Tolerance in Autoimmune Diseases
J. A. Bluestone, H Bour
Cold Spring Harbor Perspectives in Biology (2012) Vol. 4, Iss. 11, pp. a007542-a007542
Open Access | Times Cited: 64
The rise, fall, and resurgence of immunotherapy in type 1 diabetes
Moufida Ben Nasr, Francesca D’Addio, Vera Usuelli, et al.
Pharmacological Research (2014) Vol. 98, pp. 31-38
Closed Access | Times Cited: 61
Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion
Stephen Fitter, Kate Vandyke, Stan Gronthos, et al.
Journal of Molecular Endocrinology (2012) Vol. 48, Iss. 3, pp. 229-240
Open Access | Times Cited: 61
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
Alessandra Iurlo, Emanuela Orsi, Daniele Cattaneo, et al.
Oncotarget (2015) Vol. 6, Iss. 32, pp. 33944-33951
Open Access | Times Cited: 60
Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy
Mary Barber, Michael J. Mauro, Javid J. Moslehi
Hematology (2017) Vol. 2017, Iss. 1, pp. 110-114
Open Access | Times Cited: 51
Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice
Carla J. Greenbaum, Dana VanBuecken, Sandra Lord
Drugs (2019) Vol. 79, Iss. 1, pp. 43-61
Open Access | Times Cited: 46
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
Mária Krchniaková, J. Škoda, Jakub Neradil, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3157-3157
Open Access | Times Cited: 44
Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review
Takudzwa Mugiya, Mamosheledi Mothibe, Andile Khathi, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
The Immune Tolerance Network at 10 years: tolerance research at the bedside
Jeffrey A. Bluestone, Hugh Auchincloss, Gerald T. Nepom, et al.
Nature reviews. Immunology (2010) Vol. 10, Iss. 11, pp. 797-803
Closed Access | Times Cited: 60

Scroll to top